With the New Year up and running, we all got together in Aachen for a Board Meeting. In addition to mapping out activities for 2024, we focused on two additional areas.
The first was a strategic review of our services and how these align with our client’s needs. While we’re receiving superb feedback in our client surveys, we’re always thinking about further optimising how we work and what more we can do to support our partners and clients. Learning what activities add most value and trying to make them even better is very important to us.
(We’re quite happy to be able to share some of the feedback on our website, and if you haven’t seen it yet, you can take a look here).
Secondly, we’ve reviewed and discussed recent developments in the treatment of fibrotic lung disease, specifically IPF. A lot has changed since our review of the R&D landscape in 2020, with some clinical programs being stopped and others newly starting – and in many ways, challenges in lung fibrosis are prototypical of challenges in other disease areas. We may have more to say about IPF, so stay tuned.
Coincidentally, our Board Meeting happened on the same weekend that also saw the very first Parkrun in Aachen. Bob, Darcey, and Peter participated in the race – it was a great day with packed snow on the course, along with sunshine, and blue skies.
Keep an eye on our news page to see the latest updates from the TherapeutAix team.